On Tuesday, Tempus AI reached an important technical milestone, with its Relative Strength (RS) Rating moving into the 90-plus percentile with an improvement to 92, up from 89 the day before.
How To Use Stock Charts To Stay Profitable And Protected
IBD's unique rating measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks typically have an 80 or better RS Rating in the early stages of their moves.
Tempus AI is not currently offering a proper buying opportunity. See if the stock goes on to form a chart pattern that could ignite a new run.
Tempus AI posted 0% EPS growth in the latest quarterly report, while sales growth came in at 75%. The next quarterly numbers are expected on or around Aug. 12.
The company earns the No. 8 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings, Agilent Technologies and Charles River Labs Intl are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
